补足大用量维他命D削减新冠失踪信誉风险
2020年6-8月展开的几项小型多办事中心乱数对照乱数临床科学研究[1]（NCT04449718）中，240名急诊新冠病人被分为三组，依次回绝承受20万IU维他命D3或慰藉剂至多静脉打针干预。结论表白，维他命D3组的血浆25-甲基维他命D水准如预期增高（21->44ng/mL），不外，与慰藉剂组较之，补足大用量D3的组发作率反倒增高了（7.0% VS 5.1%）。
除此以外，各组阐发还辨认出，血浆维他命D贫乏者补足维他命D后发作率是不补足者的4倍多（7.1% VS 1.7%），换句话说，若是贫乏维他命D，补足维他命D反倒可能将大幅削减发作率。
2022年9月登载的几项针对该科学研究的1年筛查[2]辨认出，维他命D组的骨蒸失踪率、关节无力失踪率、呼吸困难和听力瑕疵爆发率均低于慰藉剂组；维他命D组的急性急性频次显著低于慰藉剂组。
2022年2月登载的几项548人参予的多办事中心乱数对照科学研究[3]（COVID-VIT-D测试）中，三组住院治疗病人依次回绝承受至多10万IU维他命D或慰藉剂干预。结论表白，维他命D组的发作率低于慰藉剂组（8% VS 5.6%）。
2022年5月登载的几项218人参予的多办事中心乱数对照科学研究[4]（CARED测试）中，三组参与者依次回绝承受至多50万IU的维他命D3或慰藉剂干预。结论表白，维他命D组的发作率是慰藉剂组的2.2倍（4.3% VS 1.9%）。
2022年9月，几项6200人参予的维他命D干预新冠的四期临床科学研究[5]（CORONAVIT测试，NCT04579640）结论揭晓。该科学研究辨认出，补足维他命D（800IU或3200IU/天）与明显改善新冠毫无关系；除此以外，统计数据还表白，与未补足组较之，补足800IU/天的组新冠瘦削率更高（+24%），补足3200IU/天的组住院治疗率更高（+10%）。
该科学研究的几项子科学研究[6]辨认出，在施打抗生素的人群中，补足维他命D的组打破传染信誉风险更高。
鱼油所含维他命D。2022年9月登载的几项34601人参予的四盲乱数科学研究[7]（CLOC测试，NCT04609423）结论表白，补足鱼油6个月（5mL/天，含10µg合400IU维他命D）与新冠明显改善毫无关系；统计数据还表白，与慰藉剂较之，鱼油组的新冠急诊率更高；在45岁以下的年轻人中，鱼油组的瘦削率和急诊信誉风险更高。
2021年登载的几项科学研究[8]纳入了324例新冠疑似病例，此中有38名病人被陈述利用维他命D（约800IU/天）。该科学研究辨认出，补足维他命D的病人的血浆维他命D水准是未补足者的3倍（32.9 VS 13.2 ng/mL），不外，补足维他命D病人的发作率低于未补足者（38.9% VS 26.3%）。
维他命D反例：新冠与维他命D水准持续走低？许多察看性科学研究[9]辨认出血浆维他命D含量与新冠爆发和发作率持续走低，不外那其实不能申明贫乏维他命D是新冠的其原因。
有科学研究[10][11][12]指出，包罗新冠在内的急性疾病会招致血浆维他命D水准下降[13]，因而两者可能将是逆向两者之间，换句话说，低水准的血浆维他命D是新冠的结论而非其原因。
许多Ramanathapuram科学研究[14]辨认出了补足维他命D与降低新冠信誉风险相关，不外，Ramanathapuram科学研究遭到其他因素影响，例如，主动补足维他命D的参与者具备更高的摄生之道防雷才能。
现实上，数项基于生物学的科学研究[15][16][17]排除了血浆维他命D与新冠之间的两者之间。除此以外，那些科学研究还辨认出，增高的血浆维他命D水准反倒与更高的新冠住院治疗信誉风险相关。换句话说，进步血浆维他命D水准对新冠治疗是合宪以至是倒霉的。
维他命D卵白（VDR）在细胞中与维他命D连系，参与微量元素新陈代谢。Taq I TT基因型与高水准的VDR表达[18]和较差的急诊新冠预后[19]相关；因而，高水准的VDR可能将与新冠预后不良相关。
替米沙坦是一种抗高血压药物，可大幅降低新冠失踪信誉风险（-80%）[20]。科学研究[21]辨认出，替米沙坦是VDR卵白的强拮抗剂，那正好与维他命D的感化相反。
ACE2卵白是新冠病毒进入体内的关键卵白。科学研究[22]辨认出，骨化三醇（维他命D的活性形式）削减了内毒素处置的鼠肺ACE2表达。
参考^Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, Silva CBR, Franco AS, Macedo MB, Dalmolin HHH, Baggio J, Balbi GGM, Reis BZ, Antonangelo L, Caparbo VF, Gualano B, Pereira RMR. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021 Mar 16;325(11):1053-1060. doi: 10.1001/jama.2020.26848. PMID: 33595634; PMCID: PMC7890452.^Fernandes AL, Sales LP, Santos MD, Caparbo VF, Murai IH, Pereira RMR. Persistent or new symptoms 1 year after a single high dose of vitamin D3 in patients with moderate to severe COVID-19. Front Nutr. 2022 Sep 13;9:979667. doi: 10.3389/fnut.2022.979667. PMID: 36176639; PMCID: PMC9513442.^Cannata-Andía JB, Díaz-Sottolano A, Fernández P, Palomo-Antequera C, Herrero-Puente P, Mouzo R, Carrillo-López N, Panizo S, Ibañez GH, Cusumano CA, Ballarino C, Sánchez-Polo V, Pefaur-Penna J, Maderuelo-Riesco I, Calviño-Varela J, Gómez MD, Gómez-Alonso C, Cunningham J, Naves-Díaz M, Douthat W, Fernández-Martín JL; COVID-VIT-D trial collaborators. A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial. BMC Med. 2022 Feb 18;20(1):83. doi: 10.1186/s12916-022-02290-8. PMID: 35177066; PMCID: PMC8853840.^Mariani J, Antonietti L, Tajer C, Ferder L, Inserra F, Sanchez Cunto M, Brosio D, Ross F, Zylberman M, López DE, Luna Hisano C, Maristany Batisda S, Pace G, Salvatore A, Hogrefe JF, Turela M, Gaido A, Rodera B, Banega E, Iglesias ME, Rzepeski M, Gomez Portillo JM, Bertelli M, Vilela A, Heffner L, Annetta VL, Moracho L, Carmona M, Melito G, Martínez MJ, Luna G, Vensentini N, Manucha W. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: Multicentre randomized controlled clinical trial. PLoS One. 2022 May 27;17(5):e0267918. doi: 10.1371/journal.pone.0267918. PMID: 35622854; PMCID: PMC9140264.^Jolliffe DA, Holt H, Greenig M, Talaei M, Perdek N, Pfeffer P, Vivaldi G, Maltby S, Symons J, Barlow NL, Normandale A, Garcha R, Richter AG, Faustini SE, Orton C, Ford D, Lyons RA, Davies GA, Kee F, Griffiths CJ, Norrie J, Sheikh A, Shaheen SO, Relton C, Martineau AR. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). BMJ. 2022 Sep 7;378:e071230. doi: 10.1136/bmj-2022-071230. PMID: 36215226; PMCID: PMC9449358.^Jolliffe DA, Vivaldi G, Chambers ES, Cai W, Li W, Faustini SE, Gibbons JM, Pade C, Coussens AK, Richter AG, McKnight Á, Martineau AR. Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial. Nutrients. 2022 Sep 16;14(18):3821. doi: 10.3390/nu14183821. PMID: 36145196; PMCID: PMC9506404.^Brunvoll SH, Nygaard AB, Ellingjord-Dale M, Holland P, Istre MS, Kalleberg KT, Søraas CL, Holven KB, Ulven SM, Hjartåker A, Haider T, Lund-Johansen F, Dahl JA, Meyer HE, Søraas A. Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial. BMJ. 2022 Sep 7;378:e071245. doi: 10.1136/bmj-2022-071245. PMID: 36215222; PMCID: PMC9449357.^Cereda E, Bogliolo L, Lobascio F, Barichella M, Zecchinelli AL, Pezzoli G, Caccialanza R. Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy. Nutrition. 2021 Feb;82:111055. doi: 10.1016/j.nut.2020.111055. Epub 2020 Nov 11. PMID: 33288411; PMCID: PMC7657015.^Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health. 2020 Oct;13(10):1373-1380. doi: 10.1016/j.jiph.2020.06.021. Epub 2020 Jun 20. PMID: 32605780; PMCID: PMC7305922.^Oscanoa, T. J., Ghashut, R. A., Carvajal, A., & Romero-Ortuno, R. (2022). Association between low serum vitamin D and increased mortality and severity due to COVID-19: reverse causality?. Disaster and Emergency Medicine Journal, 7(2), 124-131.^Antonelli M, Kushner I. Low Serum Levels of 25-Hydroxyvitamin D Accompany Severe COVID-19 Because it is a Negative Acute Phase Reactant. Am J Med Sci. 2021 Sep;362(3):333-335. doi: 10.1016/j.amjms.2021.06.005. Epub 2021 Jun 22. PMID: 34166653; PMCID: PMC8216860.^Smolders J, van den Ouweland J, Geven C, Pickkers P, Kox M. Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence. Metabolism. 2021 Feb;115:154434. doi: 10.1016/j.metabol.2020.154434. Epub 2020 Nov 17. PMID: 33217408; PMCID: PMC7671645.^Silva MC, Furlanetto TW. Does serum 25-hydroxyvitamin D decrease during acute-phase response? A systematic review. Nutr Res. 2015 Feb;35(2):91-6. doi: 10.1016/j.nutres.2014.12.008. Epub 2014 Dec 31. PMID: 25631715.^Gibbons JB, Norton EC, McCullough JS, Meltzer DO, Lavigne J, Fiedler VC, Gibbons RD. Association between vitamin D supplementation and COVID-19 infection and mortality. Sci Rep. 2022 Nov 12;12(1):19397. doi: 10.1038/s41598-022-24053-4. PMID: 36371591; PMCID: PMC9653496.^Butler-Laporte G, Nakanishi T, Mooser V, Morrison DR, Abdullah T, Adeleye O, Mamlouk N, Kimchi N, Afrasiabi Z, Rezk N, Giliberti A, Renieri A, Chen Y, Zhou S, Forgetta V, Richards JB. Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study. PLoS Med. 2021 Jun 1;18(6):e1003605. doi: 10.1371/journal.pmed.1003605. PMID: 34061844; PMCID: PMC8168855.^Cui Z, Tian Y. Using genetic variants to evaluate the causal effect of serum vitamin D concentration on COVID-19 susceptibility, severity and hospitalization traits: a Mendelian randomization study. J Transl Med. 2021 Jul 10;19(1):300. doi: 10.1186/s12967-021-02973-5. PMID: 34246301; PMCID: PMC8271325.^Patchen BK, Clark AG, Gaddis N, Hancock DB, Cassano PA. Genetically predicted serum vitamin D and COVID-19: a Mendelian randomisation study. BMJ Nutr Prev Health. 2021 May 4;4(1):213-225. doi: 10.1136/bmjnph-2021-000255. PMID: 34308129; PMCID: PMC8098235.^Ogunkolade BW, Boucher BJ, Prahl JM, Bustin SA, Burrin JM, Noonan K, North BV, Mannan N, McDermott MF, DeLuca HF, Hitman GA. Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes. 2002 Jul;51(7):2294-300. doi: 10.2337/diabetes.51.7.2294. PMID: 12086963.^Apaydin T, Polat H, Dincer Yazan C, Ilgin C, Elbasan O, Dashdamirova S, Bayram F, Tukenmez Tigen E, Unlu O, Tekin AF, Arslan E, Yilmaz I, Haklar G, Ata P, Gozu H. Effects of vitamin D receptor gene polymorphisms on the prognosis of COVID-19. Clin Endocrinol (Oxf). 2022 Jun;96(6):819-830. doi: 10.1111/cen.14664. Epub 2021 Dec 25. PMID: 34919268.^Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, Azzato F, Castro M, Coyle J, Davolos I, Criado IF, Gregori R, Mastrodonato P, Rubio MC, Sarquis S, Wahlmann F, Rothlin RP. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. EClinicalMedicine. 2021 Jun 18;37:100962. doi: 10.1016/j.eclinm.2021.100962. PMID: 34189447; PMCID: PMC8225700.^Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model. 2006 Jan 10;3:1. doi: 10.1186/1742-4682-3-1. PMID: 16403216; PMCID: PMC1360063.^Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide‑induced acute lung injury via regulation of the renin‑angiotensin system. Mol Med Rep. 2017 Nov;16(5):7432-7438. doi: 10.3892/mmr.2017.7546. Epub 2017 Sep 20. PMID: 28944831; PMCID: PMC5865875.
0